Benitec Biopharma (NASDAQ:BNTC) Price Target Raised to $18.27

Benitec Biopharma (NASDAQ:BNTC – Free Report) had its price target lifted by Leerink Partners from $18.00 to $18.27 in a research report sent to investors on Monday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other research firms have also issued reports on BNTC. HC Wainwright restated a “buy” rating on shares of Benitec Biopharma in a report on Monday, November 2nd. Royal Bank Of Canada raised shares of Benitec Biopharma to an “outperform” rating in a research note on Tuesday, September 15th. Wall Street Zen lowered shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Raymond James Financial initiated coverage on shares of Benitec Biopharma in a research report on Friday, October 23rd. They set an “outperform” rating and a $14.00 price objective on the stock. Finally, Wedbush boosted their target price on shares of Benitec Biopharma from $17.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.85.

Check Out Our Latest Report on Benitec Biopharma

Benitec Biopharma Stock Up 1.5%

NASDAQ:BNTC opened at $8.27 on Monday. Benitec Biopharma has a 1-year low of $7.89 and a 1-year high of $14.39. The firm has a market capitalization of $298.71 million, a price-to-earnings ratio of -8.11 and a beta of 0.26. The stock has a fifty day simple moving average of $9.41 and a 200 day simple moving average of $11.33.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. Equities analysts predict that Benitec Biopharma will post -1.31 earnings per share for the current year.

Institutional Investors Weigh In On Benitec Biopharma

A number of large investors have recently bought and sold shares of BNTC. AWM Investment Company Inc. bought a new stake in Benitec Biopharma during the 2nd quarter valued at approximately $2,515,000. Bank of New York Mellon Corp acquired a new stake in shares of Benitec Biopharma in the second quarter valued at $804,000. Goldman Sachs Group Inc. raised its holdings in shares of Benitec Biopharma by 8.7% in the third quarter. Goldman Sachs Group Inc. now owns 193,550 shares of the biotechnology company’s stock valued at $1,936,000 after buying an additional 15,509 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Benitec Biopharma by 12.7% in the third quarter. Nantahala Capital Management LLC now owns 1,677,567 shares of the biotechnology company’s stock valued at $16,776,000 after buying an additional 189,196 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Benitec Biopharma by 43.3% during the 1st quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock worth $185,000 after buying an additional 5,251 shares in the last quarter. 52.19% of the stock is currently owned by institutional investors.

About Benitec Biopharma

(Get Free Report)

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.

Further Reading

Analyst Recommendations for Benitec Biopharma (NASDAQ:BNTC)

Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.